Skip to content
OpenCapital
Get started

Celldex Therapeutics CLDX EBIT

EBIT at other companies

Rogers Corporation logo
Rogers CorporationROG
$10.7M+3,667%
Eli Lilly logo
Eli LillyLLY
——
Pfizer logo
PfizerPFE
——
Amgen logo
AmgenAMGN
——
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
——
Incyte logo
IncyteINCY
——

Other financials

Income statement

See full
Revenue$15.0K-97.8%
Operating income-$84.4M-34.6%
Net income-$78.7M-46.3%
EPS (diluted)-$1.18-45.7%

Balance sheet

See full
Cash & equivalents$35.7M+109%
Total debt$1.9M-44.3%
Total equity$456.2M-35.1%
Total assets$511.3M-30.9%

Cash flow

See full
Operating cash flow-$65.6M-20.6%
CapEx$1.6M+518%
Free cash flow-$67.2M-23.0%

Valuation

See full
Market cap$2.59B+75.2%
Enterprise value$2.55B+74.4%
P/S2,989.2×+2,794×

Profitability

See full
Operating margin-35,688.5%-39,114pp
Net margin-32,753.6%-35,519pp
FCF margin-26,125.8%-28,907pp

Returns & leverage

See full
Return on equity-48.9%-498pp
Debt / equity0×0.0×
Current ratio8.9×-12.7×

Where this comes from

Calculated from Celldex Therapeutics’s reported figures.

−$84.4Moperating income=-$84.44M

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celldex Therapeutics's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celldex Therapeutics's EBIT?
Celldex Therapeutics (CLDX) reported EBIT of -$84.44M in Q1 2026.
How has Celldex Therapeutics's EBIT changed year-over-year?
Celldex Therapeutics's EBIT decreased by 34.6% year-over-year, from -$62.74M to -$84.44M.
What is the long-term trend for Celldex Therapeutics's EBIT?
Over 4 years (2021 to 2025), Celldex Therapeutics's EBIT has grown at a 41.7% compound annual growth rate (CAGR), from -$71.24M to -$287.37M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.